Enoxaparin for the long-term therapy of VTE in patients with cancer and renal insufficiency. The RIETECAT-RI study
KEY TAKEAWAY
This study used the RIETE registry to compare the effectiveness and safety of recommended doses of enoxaparin in patients with active cancer and several grades of renal insufficiency (RI)
Only 10% of cancer patients with VTE and severe RI received recommended doses of enoxaparin in real life, which was associated with an increased risk for major bleeding
WHY THIS MATTERS
- The optimal dose of enoxaparin for treating VTE in patients with cancer and RI was not evaluated consistently
- This study* analyzed the effectiveness and safety of recommended doses of enoxaparin† in patients with active cancer and multiple grades of RI
KEY RESULTS
3,769 cancer patients with VTE and RI received enoxaparin monotherapy ( Time period: January 2009 – June 2022)
Patients were categorized based on CrCl levels:
Please click on the hyperlink, for additional details on major bleeding, all-cause mortality, and VTE recurrences in all patients irrespective of the doses received
Rates of VTE recurrences, major bleeding, non-major bleeding, and all-cause death according to enoxaparin doses
*Used data from the RIETE registry
† (vs. higher- or lower-)
ABBREVIATIONS:
aHR, adjusted hazards ratio; CAT, cancer-associated thrombosis; CrCl, creatinine clearance; CI, confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; RI, renal insufficiency; RIETE, The Computerized Registry of Patients with Venous Thromboembolism; VTE, venous thromboembolism
Reference
Monreal M, et al. Enoxaparin for the long-term therapy of VTE in patients with cancer and renal insufficiency. The RIETECAT-RI study (Poster number: PB0483). Presented at 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH 2023) on June 25, 2023.
Interested to know more about our products?
Disclaimer: For the use of a registered medical practitioner or a hospital or a laboratory only.
